nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—skin cancer—bone cancer	0.43	1	CtDrD
Vemurafenib—BRAF—bone cancer	0.283	0.818	CbGaD
Vemurafenib—CYP3A4—bone cancer	0.0629	0.182	CbGaD
Vemurafenib—ABCC1—Epirubicin—bone cancer	0.0395	0.231	CbGbCtD
Vemurafenib—ABCG2—Carboplatin—bone cancer	0.0245	0.143	CbGbCtD
Vemurafenib—ABCC1—Doxorubicin—bone cancer	0.021	0.123	CbGbCtD
Vemurafenib—ABCG2—Cisplatin—bone cancer	0.021	0.122	CbGbCtD
Vemurafenib—ABCC1—Methotrexate—bone cancer	0.0203	0.119	CbGbCtD
Vemurafenib—ABCG2—Doxorubicin—bone cancer	0.0141	0.0821	CbGbCtD
Vemurafenib—ABCG2—Methotrexate—bone cancer	0.0136	0.0795	CbGbCtD
Vemurafenib—ALB—Methotrexate—bone cancer	0.00938	0.0548	CbGbCtD
Vemurafenib—CYP2D6—Doxorubicin—bone cancer	0.00477	0.0279	CbGbCtD
Vemurafenib—CYP3A4—Doxorubicin—bone cancer	0.00304	0.0177	CbGbCtD
Vemurafenib—Etoricoxib—CYP3A4—bone cancer	0.000743	0.505	CrCbGaD
Vemurafenib—Etoricoxib—PTGS2—bone cancer	0.000727	0.495	CrCbGaD
Vemurafenib—Sunburn—Methotrexate—bone cancer	0.000486	0.0281	CcSEcCtD
Vemurafenib—Rash papular—Epirubicin—bone cancer	0.000369	0.0213	CcSEcCtD
Vemurafenib—Hepatotoxicity—Cisplatin—bone cancer	0.000346	0.02	CcSEcCtD
Vemurafenib—Rash papular—Doxorubicin—bone cancer	0.000341	0.0197	CcSEcCtD
Vemurafenib—Infection—Carboplatin—bone cancer	0.000323	0.0187	CcSEcCtD
Vemurafenib—Erythema nodosum—Epirubicin—bone cancer	0.000317	0.0183	CcSEcCtD
Vemurafenib—Erythema nodosum—Doxorubicin—bone cancer	0.000294	0.017	CcSEcCtD
Vemurafenib—Body temperature increased—Carboplatin—bone cancer	0.000257	0.0149	CcSEcCtD
Vemurafenib—Polyp—Methotrexate—bone cancer	0.000241	0.0139	CcSEcCtD
Vemurafenib—Folliculitis—Methotrexate—bone cancer	0.000233	0.0135	CcSEcCtD
Vemurafenib—Polyp—Epirubicin—bone cancer	0.000226	0.013	CcSEcCtD
Vemurafenib—Cyst—Methotrexate—bone cancer	0.000219	0.0127	CcSEcCtD
Vemurafenib—Folliculitis—Epirubicin—bone cancer	0.000218	0.0126	CcSEcCtD
Vemurafenib—Paralysis—Methotrexate—bone cancer	0.000211	0.0122	CcSEcCtD
Vemurafenib—Polyp—Doxorubicin—bone cancer	0.000209	0.0121	CcSEcCtD
Vemurafenib—Cyst—Epirubicin—bone cancer	0.000205	0.0119	CcSEcCtD
Vemurafenib—Folliculitis—Doxorubicin—bone cancer	0.000202	0.0117	CcSEcCtD
Vemurafenib—Paralysis—Epirubicin—bone cancer	0.000198	0.0114	CcSEcCtD
Vemurafenib—Cyst—Doxorubicin—bone cancer	0.00019	0.011	CcSEcCtD
Vemurafenib—Hepatotoxicity—Methotrexate—bone cancer	0.00019	0.011	CcSEcCtD
Vemurafenib—Paralysis—Doxorubicin—bone cancer	0.000183	0.0106	CcSEcCtD
Vemurafenib—Rigors—Epirubicin—bone cancer	0.000168	0.00972	CcSEcCtD
Vemurafenib—Neoplasm malignant—Epirubicin—bone cancer	0.000161	0.00929	CcSEcCtD
Vemurafenib—Rigors—Doxorubicin—bone cancer	0.000156	0.00899	CcSEcCtD
Vemurafenib—Vasculitis—Methotrexate—bone cancer	0.00015	0.00868	CcSEcCtD
Vemurafenib—Neoplasm malignant—Doxorubicin—bone cancer	0.000149	0.00859	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Cisplatin—bone cancer	0.000147	0.00847	CcSEcCtD
Vemurafenib—Musculoskeletal pain—Epirubicin—bone cancer	0.000139	0.00803	CcSEcCtD
Vemurafenib—Neoplasm—Methotrexate—bone cancer	0.000133	0.00766	CcSEcCtD
Vemurafenib—Connective tissue disorder—Cisplatin—bone cancer	0.000132	0.00762	CcSEcCtD
Vemurafenib—Musculoskeletal pain—Doxorubicin—bone cancer	0.000129	0.00743	CcSEcCtD
Vemurafenib—Eye disorder—Cisplatin—bone cancer	0.000125	0.00725	CcSEcCtD
Vemurafenib—Rash maculo-papular—Epirubicin—bone cancer	0.000125	0.00721	CcSEcCtD
Vemurafenib—Cardiac disorder—Cisplatin—bone cancer	0.000125	0.0072	CcSEcCtD
Vemurafenib—Neoplasm—Epirubicin—bone cancer	0.000124	0.00717	CcSEcCtD
Vemurafenib—Photosensitivity—Methotrexate—bone cancer	0.000121	0.00701	CcSEcCtD
Vemurafenib—Mediastinal disorder—Cisplatin—bone cancer	0.000121	0.00699	CcSEcCtD
Vemurafenib—Alopecia—Cisplatin—bone cancer	0.000119	0.00685	CcSEcCtD
Vemurafenib—Erythema—Cisplatin—bone cancer	0.000117	0.00675	CcSEcCtD
Vemurafenib—Malnutrition—Cisplatin—bone cancer	0.000117	0.00675	CcSEcCtD
Vemurafenib—Rash maculo-papular—Doxorubicin—bone cancer	0.000115	0.00667	CcSEcCtD
Vemurafenib—Neoplasm—Doxorubicin—bone cancer	0.000115	0.00664	CcSEcCtD
Vemurafenib—Photosensitivity—Epirubicin—bone cancer	0.000113	0.00656	CcSEcCtD
Vemurafenib—Photosensitivity—Doxorubicin—bone cancer	0.000105	0.00607	CcSEcCtD
Vemurafenib—Pain in extremity—Epirubicin—bone cancer	9.97e-05	0.00576	CcSEcCtD
Vemurafenib—Myalgia—Cisplatin—bone cancer	9.95e-05	0.00575	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	9.88e-05	0.00571	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Methotrexate—bone cancer	9.59e-05	0.00554	CcSEcCtD
Vemurafenib—Anaphylactic shock—Cisplatin—bone cancer	9.54e-05	0.00551	CcSEcCtD
Vemurafenib—Infection—Cisplatin—bone cancer	9.48e-05	0.00547	CcSEcCtD
Vemurafenib—Nervous system disorder—Cisplatin—bone cancer	9.35e-05	0.0054	CcSEcCtD
Vemurafenib—Skin disorder—Cisplatin—bone cancer	9.26e-05	0.00535	CcSEcCtD
Vemurafenib—Pain in extremity—Doxorubicin—bone cancer	9.22e-05	0.00533	CcSEcCtD
Vemurafenib—Dry skin—Epirubicin—bone cancer	9.13e-05	0.00528	CcSEcCtD
Vemurafenib—Eosinophilia—Methotrexate—bone cancer	9.11e-05	0.00527	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Epirubicin—bone cancer	8.97e-05	0.00518	CcSEcCtD
Vemurafenib—Hypotension—Cisplatin—bone cancer	8.91e-05	0.00515	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Cisplatin—bone cancer	8.69e-05	0.00502	CcSEcCtD
Vemurafenib—Eosinophilia—Epirubicin—bone cancer	8.53e-05	0.00493	CcSEcCtD
Vemurafenib—Dry skin—Doxorubicin—bone cancer	8.45e-05	0.00488	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Methotrexate—bone cancer	8.4e-05	0.00485	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Doxorubicin—bone cancer	8.3e-05	0.0048	CcSEcCtD
Vemurafenib—Decreased appetite—Cisplatin—bone cancer	8.29e-05	0.00479	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Cisplatin—bone cancer	8.23e-05	0.00476	CcSEcCtD
Vemurafenib—Infestation NOS—Methotrexate—bone cancer	8.21e-05	0.00474	CcSEcCtD
Vemurafenib—Infestation—Methotrexate—bone cancer	8.21e-05	0.00474	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Methotrexate—bone cancer	8.14e-05	0.0047	CcSEcCtD
Vemurafenib—Eosinophilia—Doxorubicin—bone cancer	7.89e-05	0.00456	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Epirubicin—bone cancer	7.86e-05	0.00454	CcSEcCtD
Vemurafenib—Weight decreased—Epirubicin—bone cancer	7.79e-05	0.0045	CcSEcCtD
Vemurafenib—Infestation—Epirubicin—bone cancer	7.68e-05	0.00444	CcSEcCtD
Vemurafenib—Infestation NOS—Epirubicin—bone cancer	7.68e-05	0.00444	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Epirubicin—bone cancer	7.61e-05	0.0044	CcSEcCtD
Vemurafenib—Body temperature increased—Cisplatin—bone cancer	7.54e-05	0.00436	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Epirubicin—bone cancer	7.53e-05	0.00435	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Doxorubicin—bone cancer	7.27e-05	0.0042	CcSEcCtD
Vemurafenib—Weight decreased—Doxorubicin—bone cancer	7.21e-05	0.00417	CcSEcCtD
Vemurafenib—Infestation—Doxorubicin—bone cancer	7.11e-05	0.00411	CcSEcCtD
Vemurafenib—Infestation NOS—Doxorubicin—bone cancer	7.11e-05	0.00411	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Doxorubicin—bone cancer	7.04e-05	0.00407	CcSEcCtD
Vemurafenib—Hypersensitivity—Cisplatin—bone cancer	7.03e-05	0.00406	CcSEcCtD
Vemurafenib—Erythema multiforme—Methotrexate—bone cancer	6.97e-05	0.00402	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Doxorubicin—bone cancer	6.97e-05	0.00402	CcSEcCtD
Vemurafenib—Eye disorder—Methotrexate—bone cancer	6.88e-05	0.00398	CcSEcCtD
Vemurafenib—Asthenia—Cisplatin—bone cancer	6.84e-05	0.00395	CcSEcCtD
Vemurafenib—Cardiac disorder—Methotrexate—bone cancer	6.84e-05	0.00395	CcSEcCtD
Vemurafenib—Oedema peripheral—Epirubicin—bone cancer	6.79e-05	0.00392	CcSEcCtD
Vemurafenib—Connective tissue disorder—Epirubicin—bone cancer	6.77e-05	0.00391	CcSEcCtD
Vemurafenib—Angiopathy—Methotrexate—bone cancer	6.68e-05	0.00386	CcSEcCtD
Vemurafenib—Mediastinal disorder—Methotrexate—bone cancer	6.64e-05	0.00384	CcSEcCtD
Vemurafenib—Chills—Methotrexate—bone cancer	6.61e-05	0.00382	CcSEcCtD
Vemurafenib—Diarrhoea—Cisplatin—bone cancer	6.53e-05	0.00377	CcSEcCtD
Vemurafenib—Erythema multiforme—Epirubicin—bone cancer	6.52e-05	0.00377	CcSEcCtD
Vemurafenib—Alopecia—Methotrexate—bone cancer	6.51e-05	0.00376	CcSEcCtD
Vemurafenib—Eye disorder—Epirubicin—bone cancer	6.44e-05	0.00372	CcSEcCtD
Vemurafenib—Erythema—Methotrexate—bone cancer	6.41e-05	0.00371	CcSEcCtD
Vemurafenib—Malnutrition—Methotrexate—bone cancer	6.41e-05	0.00371	CcSEcCtD
Vemurafenib—Cardiac disorder—Epirubicin—bone cancer	6.4e-05	0.0037	CcSEcCtD
Vemurafenib—Oedema peripheral—Doxorubicin—bone cancer	6.28e-05	0.00363	CcSEcCtD
Vemurafenib—Dysgeusia—Methotrexate—bone cancer	6.28e-05	0.00363	CcSEcCtD
Vemurafenib—Connective tissue disorder—Doxorubicin—bone cancer	6.27e-05	0.00362	CcSEcCtD
Vemurafenib—Angiopathy—Epirubicin—bone cancer	6.25e-05	0.00361	CcSEcCtD
Vemurafenib—Mediastinal disorder—Epirubicin—bone cancer	6.21e-05	0.00359	CcSEcCtD
Vemurafenib—Back pain—Methotrexate—bone cancer	6.2e-05	0.00358	CcSEcCtD
Vemurafenib—Chills—Epirubicin—bone cancer	6.19e-05	0.00357	CcSEcCtD
Vemurafenib—Alopecia—Epirubicin—bone cancer	6.09e-05	0.00352	CcSEcCtD
Vemurafenib—Vomiting—Cisplatin—bone cancer	6.06e-05	0.0035	CcSEcCtD
Vemurafenib—Erythema multiforme—Doxorubicin—bone cancer	6.03e-05	0.00348	CcSEcCtD
Vemurafenib—Rash—Cisplatin—bone cancer	6.01e-05	0.00347	CcSEcCtD
Vemurafenib—Dermatitis—Cisplatin—bone cancer	6.01e-05	0.00347	CcSEcCtD
Vemurafenib—Erythema—Epirubicin—bone cancer	6e-05	0.00347	CcSEcCtD
Vemurafenib—Malnutrition—Epirubicin—bone cancer	6e-05	0.00347	CcSEcCtD
Vemurafenib—Eye disorder—Doxorubicin—bone cancer	5.96e-05	0.00344	CcSEcCtD
Vemurafenib—Cardiac disorder—Doxorubicin—bone cancer	5.92e-05	0.00342	CcSEcCtD
Vemurafenib—Dysgeusia—Epirubicin—bone cancer	5.88e-05	0.0034	CcSEcCtD
Vemurafenib—Back pain—Epirubicin—bone cancer	5.81e-05	0.00335	CcSEcCtD
Vemurafenib—Angiopathy—Doxorubicin—bone cancer	5.79e-05	0.00334	CcSEcCtD
Vemurafenib—Mediastinal disorder—Doxorubicin—bone cancer	5.75e-05	0.00332	CcSEcCtD
Vemurafenib—Chills—Doxorubicin—bone cancer	5.72e-05	0.00331	CcSEcCtD
Vemurafenib—Nausea—Cisplatin—bone cancer	5.67e-05	0.00327	CcSEcCtD
Vemurafenib—Alopecia—Doxorubicin—bone cancer	5.64e-05	0.00326	CcSEcCtD
Vemurafenib—Cough—Methotrexate—bone cancer	5.6e-05	0.00323	CcSEcCtD
Vemurafenib—Malnutrition—Doxorubicin—bone cancer	5.55e-05	0.00321	CcSEcCtD
Vemurafenib—Erythema—Doxorubicin—bone cancer	5.55e-05	0.00321	CcSEcCtD
Vemurafenib—Arthralgia—Methotrexate—bone cancer	5.46e-05	0.00315	CcSEcCtD
Vemurafenib—Myalgia—Methotrexate—bone cancer	5.46e-05	0.00315	CcSEcCtD
Vemurafenib—Dysgeusia—Doxorubicin—bone cancer	5.44e-05	0.00314	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	5.42e-05	0.00313	CcSEcCtD
Vemurafenib—Back pain—Doxorubicin—bone cancer	5.37e-05	0.0031	CcSEcCtD
Vemurafenib—Cough—Epirubicin—bone cancer	5.24e-05	0.00303	CcSEcCtD
Vemurafenib—Anaphylactic shock—Methotrexate—bone cancer	5.23e-05	0.00302	CcSEcCtD
Vemurafenib—Infection—Methotrexate—bone cancer	5.2e-05	0.003	CcSEcCtD
Vemurafenib—Nervous system disorder—Methotrexate—bone cancer	5.13e-05	0.00297	CcSEcCtD
Vemurafenib—Myalgia—Epirubicin—bone cancer	5.11e-05	0.00295	CcSEcCtD
Vemurafenib—Arthralgia—Epirubicin—bone cancer	5.11e-05	0.00295	CcSEcCtD
Vemurafenib—Skin disorder—Methotrexate—bone cancer	5.08e-05	0.00294	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	5.07e-05	0.00293	CcSEcCtD
Vemurafenib—Anaphylactic shock—Epirubicin—bone cancer	4.9e-05	0.00283	CcSEcCtD
Vemurafenib—Hypotension—Methotrexate—bone cancer	4.89e-05	0.00283	CcSEcCtD
Vemurafenib—Infection—Epirubicin—bone cancer	4.87e-05	0.00281	CcSEcCtD
Vemurafenib—Cough—Doxorubicin—bone cancer	4.85e-05	0.0028	CcSEcCtD
Vemurafenib—Nervous system disorder—Epirubicin—bone cancer	4.8e-05	0.00278	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Methotrexate—bone cancer	4.77e-05	0.00276	CcSEcCtD
Vemurafenib—Skin disorder—Epirubicin—bone cancer	4.76e-05	0.00275	CcSEcCtD
Vemurafenib—Arthralgia—Doxorubicin—bone cancer	4.73e-05	0.00273	CcSEcCtD
Vemurafenib—Myalgia—Doxorubicin—bone cancer	4.73e-05	0.00273	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	4.69e-05	0.00271	CcSEcCtD
Vemurafenib—Hypotension—Epirubicin—bone cancer	4.58e-05	0.00264	CcSEcCtD
Vemurafenib—Decreased appetite—Methotrexate—bone cancer	4.55e-05	0.00263	CcSEcCtD
Vemurafenib—Anaphylactic shock—Doxorubicin—bone cancer	4.53e-05	0.00262	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Methotrexate—bone cancer	4.52e-05	0.00261	CcSEcCtD
Vemurafenib—Fatigue—Methotrexate—bone cancer	4.51e-05	0.00261	CcSEcCtD
Vemurafenib—Infection—Doxorubicin—bone cancer	4.5e-05	0.0026	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Epirubicin—bone cancer	4.46e-05	0.00258	CcSEcCtD
Vemurafenib—Nervous system disorder—Doxorubicin—bone cancer	4.44e-05	0.00257	CcSEcCtD
Vemurafenib—Skin disorder—Doxorubicin—bone cancer	4.4e-05	0.00254	CcSEcCtD
Vemurafenib—Decreased appetite—Epirubicin—bone cancer	4.26e-05	0.00246	CcSEcCtD
Vemurafenib—Hypotension—Doxorubicin—bone cancer	4.23e-05	0.00245	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Epirubicin—bone cancer	4.23e-05	0.00244	CcSEcCtD
Vemurafenib—Fatigue—Epirubicin—bone cancer	4.22e-05	0.00244	CcSEcCtD
Vemurafenib—Constipation—Epirubicin—bone cancer	4.19e-05	0.00242	CcSEcCtD
Vemurafenib—Body temperature increased—Methotrexate—bone cancer	4.14e-05	0.00239	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Doxorubicin—bone cancer	4.13e-05	0.00239	CcSEcCtD
Vemurafenib—Decreased appetite—Doxorubicin—bone cancer	3.94e-05	0.00228	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Doxorubicin—bone cancer	3.91e-05	0.00226	CcSEcCtD
Vemurafenib—Fatigue—Doxorubicin—bone cancer	3.91e-05	0.00226	CcSEcCtD
Vemurafenib—Constipation—Doxorubicin—bone cancer	3.88e-05	0.00224	CcSEcCtD
Vemurafenib—Body temperature increased—Epirubicin—bone cancer	3.87e-05	0.00224	CcSEcCtD
Vemurafenib—Hypersensitivity—Methotrexate—bone cancer	3.86e-05	0.00223	CcSEcCtD
Vemurafenib—RAF1—MAPK Signaling Pathway—BRAF—bone cancer	3.76e-05	0.00111	CbGpPWpGaD
Vemurafenib—Asthenia—Methotrexate—bone cancer	3.76e-05	0.00217	CcSEcCtD
Vemurafenib—RAF1—Signaling by PDGF—KIT—bone cancer	3.75e-05	0.0011	CbGpPWpGaD
Vemurafenib—Pruritus—Methotrexate—bone cancer	3.7e-05	0.00214	CcSEcCtD
Vemurafenib—CYP1A2—Phase II conjugation—GSTP1—bone cancer	3.7e-05	0.00109	CbGpPWpGaD
Vemurafenib—RAF1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	3.64e-05	0.00107	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—MDM2—bone cancer	3.62e-05	0.00107	CbGpPWpGaD
Vemurafenib—Hypersensitivity—Epirubicin—bone cancer	3.61e-05	0.00208	CcSEcCtD
Vemurafenib—RAF1—Signaling by FGFR in disease—BRAF—bone cancer	3.61e-05	0.00106	CbGpPWpGaD
Vemurafenib—BRAF—Focal Adhesion—JUN—bone cancer	3.59e-05	0.00106	CbGpPWpGaD
Vemurafenib—Body temperature increased—Doxorubicin—bone cancer	3.58e-05	0.00207	CcSEcCtD
Vemurafenib—Diarrhoea—Methotrexate—bone cancer	3.58e-05	0.00207	CcSEcCtD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	3.57e-05	0.00105	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—NDUFA12—bone cancer	3.52e-05	0.00103	CbGpPWpGaD
Vemurafenib—Asthenia—Epirubicin—bone cancer	3.51e-05	0.00203	CcSEcCtD
Vemurafenib—RAF1—PDGFR-beta signaling pathway—JUN—bone cancer	3.47e-05	0.00102	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling of activated FGFR—MDM2—bone cancer	3.47e-05	0.00102	CbGpPWpGaD
Vemurafenib—Pruritus—Epirubicin—bone cancer	3.47e-05	0.002	CcSEcCtD
Vemurafenib—Dizziness—Methotrexate—bone cancer	3.46e-05	0.002	CcSEcCtD
Vemurafenib—BRAF—Regulation of Actin Cytoskeleton—EGFR—bone cancer	3.43e-05	0.00101	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—SPARC—bone cancer	3.42e-05	0.00101	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB4—MDM2—bone cancer	3.41e-05	0.001	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—BRAF—bone cancer	3.41e-05	0.001	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—KIT—bone cancer	3.4e-05	0.001	CbGpPWpGaD
Vemurafenib—BRAF—Integrated Breast Cancer Pathway—EGFR—bone cancer	3.39e-05	0.000997	CbGpPWpGaD
Vemurafenib—Diarrhoea—Epirubicin—bone cancer	3.35e-05	0.00194	CcSEcCtD
Vemurafenib—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	3.34e-05	0.000983	CbGpPWpGaD
Vemurafenib—Hypersensitivity—Doxorubicin—bone cancer	3.34e-05	0.00193	CcSEcCtD
Vemurafenib—Vomiting—Methotrexate—bone cancer	3.33e-05	0.00192	CcSEcCtD
Vemurafenib—RAF1—TGF-beta Signaling Pathway—JUN—bone cancer	3.32e-05	0.000977	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—NT5C3A—bone cancer	3.31e-05	0.000974	CbGpPWpGaD
Vemurafenib—Rash—Methotrexate—bone cancer	3.3e-05	0.00191	CcSEcCtD
Vemurafenib—Dermatitis—Methotrexate—bone cancer	3.3e-05	0.0019	CcSEcCtD
Vemurafenib—Headache—Methotrexate—bone cancer	3.28e-05	0.00189	CcSEcCtD
Vemurafenib—RAF1—Transmission across Chemical Synapses—BRAF—bone cancer	3.27e-05	0.000962	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	3.27e-05	0.000961	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—MDM2—bone cancer	3.26e-05	0.000959	CbGpPWpGaD
Vemurafenib—Asthenia—Doxorubicin—bone cancer	3.25e-05	0.00188	CcSEcCtD
Vemurafenib—RAF1—Signaling by FGFR—MDM2—bone cancer	3.24e-05	0.000954	CbGpPWpGaD
Vemurafenib—Dizziness—Epirubicin—bone cancer	3.24e-05	0.00187	CcSEcCtD
Vemurafenib—RAF1—Signaling by ERBB2—MDM2—bone cancer	3.23e-05	0.000949	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	3.22e-05	0.000948	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—RGS1—bone cancer	3.21e-05	0.000946	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—GRM4—bone cancer	3.21e-05	0.000946	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—MDM2—bone cancer	3.21e-05	0.000945	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways in Glioblastoma—TP53—bone cancer	3.21e-05	0.000944	CbGpPWpGaD
Vemurafenib—Pruritus—Doxorubicin—bone cancer	3.21e-05	0.00185	CcSEcCtD
Vemurafenib—BRAF—Signaling by FGFR—EGFR—bone cancer	3.2e-05	0.000942	CbGpPWpGaD
Vemurafenib—BRAF—EGF/EGFR Signaling Pathway—EGFR—bone cancer	3.2e-05	0.000942	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—BRAF—bone cancer	3.19e-05	0.00094	CbGpPWpGaD
Vemurafenib—RAF1—ErbB1 downstream signaling—EGFR—bone cancer	3.14e-05	0.000922	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—GNA11—bone cancer	3.13e-05	0.000921	CbGpPWpGaD
Vemurafenib—Vomiting—Epirubicin—bone cancer	3.11e-05	0.0018	CcSEcCtD
Vemurafenib—BRAF—MAPK Signaling Pathway—EGFR—bone cancer	3.11e-05	0.000915	CbGpPWpGaD
Vemurafenib—Nausea—Methotrexate—bone cancer	3.11e-05	0.0018	CcSEcCtD
Vemurafenib—Diarrhoea—Doxorubicin—bone cancer	3.1e-05	0.00179	CcSEcCtD
Vemurafenib—RAF1—BDNF signaling pathway—JUN—bone cancer	3.1e-05	0.000911	CbGpPWpGaD
Vemurafenib—Rash—Epirubicin—bone cancer	3.09e-05	0.00178	CcSEcCtD
Vemurafenib—Dermatitis—Epirubicin—bone cancer	3.09e-05	0.00178	CcSEcCtD
Vemurafenib—Headache—Epirubicin—bone cancer	3.07e-05	0.00177	CcSEcCtD
Vemurafenib—RAF1—Signaling by SCF-KIT—MMP9—bone cancer	3.06e-05	0.000902	CbGpPWpGaD
Vemurafenib—RAF1—Retinoblastoma (RB) in Cancer—TP53—bone cancer	3.06e-05	0.0009	CbGpPWpGaD
Vemurafenib—BRAF—Neuronal System—MDM2—bone cancer	3.03e-05	0.000893	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—MDM2—bone cancer	3.02e-05	0.000889	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—MDM2—bone cancer	3.02e-05	0.000889	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—MDM2—bone cancer	3.02e-05	0.000889	CbGpPWpGaD
Vemurafenib—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	3.01e-05	0.000887	CbGpPWpGaD
Vemurafenib—Dizziness—Doxorubicin—bone cancer	3e-05	0.00173	CcSEcCtD
Vemurafenib—RAF1—Signaling by EGFR—MDM2—bone cancer	2.99e-05	0.000881	CbGpPWpGaD
Vemurafenib—CYP2D6—Biological oxidations—CYP3A4—bone cancer	2.99e-05	0.000879	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by FGFR in disease—EGFR—bone cancer	2.98e-05	0.000878	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—MDM2—bone cancer	2.97e-05	0.000875	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—MDM2—bone cancer	2.97e-05	0.000873	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	2.96e-05	0.000872	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—MDM2—bone cancer	2.95e-05	0.000869	CbGpPWpGaD
Vemurafenib—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	2.95e-05	0.000867	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—NT5C3A—bone cancer	2.91e-05	0.000857	CbGpPWpGaD
Vemurafenib—Nausea—Epirubicin—bone cancer	2.91e-05	0.00168	CcSEcCtD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	2.91e-05	0.000855	CbGpPWpGaD
Vemurafenib—Vomiting—Doxorubicin—bone cancer	2.88e-05	0.00166	CcSEcCtD
Vemurafenib—Rash—Doxorubicin—bone cancer	2.86e-05	0.00165	CcSEcCtD
Vemurafenib—Dermatitis—Doxorubicin—bone cancer	2.85e-05	0.00165	CcSEcCtD
Vemurafenib—RAF1—Insulin Signaling—JUN—bone cancer	2.85e-05	0.000838	CbGpPWpGaD
Vemurafenib—BRAF—Integrated Breast Cancer Pathway—TP53—bone cancer	2.85e-05	0.000837	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.84e-05	0.000836	CbGpPWpGaD
Vemurafenib—Headache—Doxorubicin—bone cancer	2.84e-05	0.00164	CcSEcCtD
Vemurafenib—RAF1—Hemostasis—IL3—bone cancer	2.84e-05	0.000835	CbGpPWpGaD
Vemurafenib—BRAF—Focal Adhesion—EGFR—bone cancer	2.82e-05	0.00083	CbGpPWpGaD
Vemurafenib—RAF1—EGF/EGFR Signaling Pathway—JUN—bone cancer	2.82e-05	0.000829	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—GRM1—bone cancer	2.79e-05	0.00082	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	2.78e-05	0.000817	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—GRM4—bone cancer	2.74e-05	0.000807	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—RGS1—bone cancer	2.74e-05	0.000807	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	2.74e-05	0.000807	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.74e-05	0.000806	CbGpPWpGaD
Vemurafenib—RAF1—Transmission across Chemical Synapses—MDM2—bone cancer	2.74e-05	0.000806	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—JUN—bone cancer	2.74e-05	0.000806	CbGpPWpGaD
Vemurafenib—Nausea—Doxorubicin—bone cancer	2.69e-05	0.00156	CcSEcCtD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—MDM2—bone cancer	2.68e-05	0.000787	CbGpPWpGaD
Vemurafenib—BRAF—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	2.64e-05	0.000778	CbGpPWpGaD
Vemurafenib—RAF1—Senescence and Autophagy in Cancer—TP53—bone cancer	2.63e-05	0.000775	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—JUN—bone cancer	2.63e-05	0.000773	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—ATF1—bone cancer	2.62e-05	0.000771	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—KIT—bone cancer	2.61e-05	0.000769	CbGpPWpGaD
Vemurafenib—BRAF—MAPK Signaling Pathway—TP53—bone cancer	2.61e-05	0.000769	CbGpPWpGaD
Vemurafenib—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	2.58e-05	0.000759	CbGpPWpGaD
Vemurafenib—CYP2D6—Biological oxidations—GSTP1—bone cancer	2.56e-05	0.000752	CbGpPWpGaD
Vemurafenib—CYP1A2—Biological oxidations—CYP3A4—bone cancer	2.53e-05	0.000745	CbGpPWpGaD
Vemurafenib—BRAF—Disease—ENO2—bone cancer	2.53e-05	0.000743	CbGpPWpGaD
Vemurafenib—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	2.52e-05	0.000742	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—MET—bone cancer	2.51e-05	0.000739	CbGpPWpGaD
Vemurafenib—RAF1—Neuronal System—BRAF—bone cancer	2.51e-05	0.000737	CbGpPWpGaD
Vemurafenib—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	2.5e-05	0.000735	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—JUN—bone cancer	2.48e-05	0.00073	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—EGFR—bone cancer	2.48e-05	0.000729	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.47e-05	0.000727	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—BRAF—bone cancer	2.46e-05	0.000723	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	2.4e-05	0.000705	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—GRM1—bone cancer	2.38e-05	0.0007	CbGpPWpGaD
Vemurafenib—RAF1—Regulation of Actin Cytoskeleton—EGFR—bone cancer	2.37e-05	0.000697	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling of activated FGFR—EGFR—bone cancer	2.37e-05	0.000697	CbGpPWpGaD
Vemurafenib—BRAF—Disease—DHFR—bone cancer	2.34e-05	0.000689	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB4—EGFR—bone cancer	2.33e-05	0.000686	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	2.28e-05	0.000672	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	2.28e-05	0.000672	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—EGFR—bone cancer	2.23e-05	0.000655	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—EGFR—bone cancer	2.22e-05	0.000652	CbGpPWpGaD
Vemurafenib—RAF1—EGF/EGFR Signaling Pathway—EGFR—bone cancer	2.22e-05	0.000652	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—EGFR—bone cancer	2.21e-05	0.000649	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—EGFR—bone cancer	2.19e-05	0.000646	CbGpPWpGaD
Vemurafenib—RAF1—TGF-beta Signaling Pathway—TP53—bone cancer	2.19e-05	0.000645	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—NDUFA12—bone cancer	2.17e-05	0.000638	CbGpPWpGaD
Vemurafenib—CYP1A2—Biological oxidations—GSTP1—bone cancer	2.17e-05	0.000637	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—EGFR—bone cancer	2.15e-05	0.000633	CbGpPWpGaD
Vemurafenib—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	2.14e-05	0.000628	CbGpPWpGaD
Vemurafenib—RAF1—Neuronal System—MDM2—bone cancer	2.1e-05	0.000618	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—MMP2—bone cancer	2.1e-05	0.000617	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—EGFR—bone cancer	2.06e-05	0.000607	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—EGFR—bone cancer	2.06e-05	0.000607	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—EGFR—bone cancer	2.06e-05	0.000607	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—MDM2—bone cancer	2.06e-05	0.000606	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—TP53—bone cancer	2.05e-05	0.000604	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—EGFR—bone cancer	2.05e-05	0.000602	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—EGFR—bone cancer	2.03e-05	0.000598	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—EGFR—bone cancer	2.03e-05	0.000597	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—EGFR—bone cancer	2.02e-05	0.000594	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—SMO—bone cancer	1.96e-05	0.000578	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—EGFR—bone cancer	1.95e-05	0.000574	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.94e-05	0.000572	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—RGS1—bone cancer	1.9e-05	0.000559	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—GRM4—bone cancer	1.9e-05	0.000559	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—PLAU—bone cancer	1.86e-05	0.000548	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—SPARC—bone cancer	1.84e-05	0.000542	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	1.83e-05	0.000538	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—TP53—bone cancer	1.81e-05	0.000532	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—NT5C3A—bone cancer	1.8e-05	0.000529	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—GNA11—bone cancer	1.8e-05	0.000528	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—CDK4—bone cancer	1.79e-05	0.000528	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—MET—bone cancer	1.79e-05	0.000528	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NDUFA12—bone cancer	1.79e-05	0.000527	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	1.77e-05	0.00052	CbGpPWpGaD
Vemurafenib—RAF1—Disease—ENO2—bone cancer	1.75e-05	0.000514	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—ENO2—bone cancer	1.73e-05	0.00051	CbGpPWpGaD
Vemurafenib—BRAF—Disease—TGFBR2—bone cancer	1.7e-05	0.0005	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—GNA11—bone cancer	1.68e-05	0.000496	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SMO—bone cancer	1.68e-05	0.000493	CbGpPWpGaD
Vemurafenib—CYP3A4—Biological oxidations—GSTP1—bone cancer	1.67e-05	0.000492	CbGpPWpGaD
Vemurafenib—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	1.65e-05	0.000485	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—GRM1—bone cancer	1.65e-05	0.000484	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.63e-05	0.00048	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL3—bone cancer	1.63e-05	0.000479	CbGpPWpGaD
Vemurafenib—RAF1—Disease—DHFR—bone cancer	1.62e-05	0.000477	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—DHFR—bone cancer	1.61e-05	0.000473	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—MMP9—bone cancer	1.58e-05	0.000463	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—GNA11—bone cancer	1.53e-05	0.000451	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—IL3—bone cancer	1.53e-05	0.000449	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—ATF1—bone cancer	1.53e-05	0.000449	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NDUFA12—bone cancer	1.52e-05	0.000447	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—MMP2—bone cancer	1.5e-05	0.00044	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—KIT—bone cancer	1.49e-05	0.000439	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL3—bone cancer	1.49e-05	0.000438	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NT5C3A—bone cancer	1.48e-05	0.000437	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ENO2—bone cancer	1.45e-05	0.000427	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—KIT—bone cancer	1.43e-05	0.000421	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—ATF1—bone cancer	1.43e-05	0.000419	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—EGFR—bone cancer	1.41e-05	0.000414	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL3—bone cancer	1.39e-05	0.000409	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—DHFR—bone cancer	1.35e-05	0.000396	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ENO2—bone cancer	1.28e-05	0.000376	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—EGFR—bone cancer	1.27e-05	0.000375	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GNA11—bone cancer	1.26e-05	0.00037	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NT5C3A—bone cancer	1.26e-05	0.00037	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TGFBR2—bone cancer	1.19e-05	0.00035	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—DHFR—bone cancer	1.18e-05	0.000348	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TGFBR2—bone cancer	1.17e-05	0.000346	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—MDM2—bone cancer	1.17e-05	0.000345	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NDUFA12—bone cancer	1.17e-05	0.000345	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TGFBR2—bone cancer	1.16e-05	0.000343	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SMO—bone cancer	1.16e-05	0.000341	CbGpPWpGaD
Vemurafenib—BRAF—Disease—KIT—bone cancer	1.16e-05	0.000341	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CYP3A4—bone cancer	1.14e-05	0.000335	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.13e-05	0.000334	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—MDM2—bone cancer	1.13e-05	0.000332	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—MMP9—bone cancer	1.12e-05	0.000331	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IGF1R—bone cancer	1.12e-05	0.000329	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GNA11—bone cancer	1.11e-05	0.000326	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—GNA11—bone cancer	1.06e-05	0.000312	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—JUN—bone cancer	1.02e-05	0.0003	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CYP3A4—bone cancer	1e-05	0.000295	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—PLAU—bone cancer	1e-05	0.000295	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—ATF1—bone cancer	9.86e-06	0.00029	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GSTP1—bone cancer	9.75e-06	0.000287	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NT5C3A—bone cancer	9.71e-06	0.000286	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL3—bone cancer	9.62e-06	0.000283	CbGpPWpGaD
Vemurafenib—BRAF—Disease—MDM2—bone cancer	9.12e-06	0.000268	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—EGFR—bone cancer	9.08e-06	0.000267	CbGpPWpGaD
Vemurafenib—BRAF—Disease—PTGS2—bone cancer	8.8e-06	0.000259	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—KIT—bone cancer	8.68e-06	0.000255	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GSTP1—bone cancer	8.58e-06	0.000252	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TGFBR2—bone cancer	8.23e-06	0.000242	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—KIT—bone cancer	8.11e-06	0.000239	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—EGFR—bone cancer	8.02e-06	0.000236	CbGpPWpGaD
Vemurafenib—RAF1—Disease—KIT—bone cancer	8.02e-06	0.000236	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—KIT—bone cancer	7.95e-06	0.000234	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—ENO2—bone cancer	7.88e-06	0.000232	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IGF1R—bone cancer	7.74e-06	0.000228	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—EGFR—bone cancer	7.7e-06	0.000227	CbGpPWpGaD
Vemurafenib—RAF1—Disease—BRAF—bone cancer	7.53e-06	0.000222	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TP53—bone cancer	7.48e-06	0.00022	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—BRAF—bone cancer	7.47e-06	0.00022	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—DHFR—bone cancer	7.31e-06	0.000215	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—MDM2—bone cancer	6.84e-06	0.000201	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GNA11—bone cancer	6.83e-06	0.000201	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ENO2—bone cancer	6.5e-06	0.000191	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MDM2—bone cancer	6.39e-06	0.000188	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MDM2—bone cancer	6.31e-06	0.000186	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MDM2—bone cancer	6.26e-06	0.000184	CbGpPWpGaD
Vemurafenib—BRAF—Disease—EGFR—bone cancer	6.24e-06	0.000183	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CYP3A4—bone cancer	6.19e-06	0.000182	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	6.16e-06	0.000181	CbGpPWpGaD
Vemurafenib—RAF1—Disease—PTGS2—bone cancer	6.09e-06	0.000179	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—DHFR—bone cancer	6.03e-06	0.000177	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—PTGS2—bone cancer	6.03e-06	0.000177	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—JUN—bone cancer	5.94e-06	0.000175	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GNA11—bone cancer	5.64e-06	0.000166	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—KIT—bone cancer	5.61e-06	0.000165	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—JUN—bone cancer	5.55e-06	0.000163	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ENO2—bone cancer	5.51e-06	0.000162	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MMP9—bone cancer	5.4e-06	0.000159	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GSTP1—bone cancer	5.3e-06	0.000156	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—BRAF—bone cancer	5.28e-06	0.000155	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—EGFR—bone cancer	5.11e-06	0.00015	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP3A4—bone cancer	5.11e-06	0.00015	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—DHFR—bone cancer	5.11e-06	0.00015	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PTGS2—bone cancer	5.05e-06	0.000149	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GNA11—bone cancer	4.78e-06	0.000141	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—EGFR—bone cancer	4.67e-06	0.000137	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PTGS2—bone cancer	4.45e-06	0.000131	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MDM2—bone cancer	4.42e-06	0.00013	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GSTP1—bone cancer	4.37e-06	0.000129	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—EGFR—bone cancer	4.37e-06	0.000128	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP3A4—bone cancer	4.33e-06	0.000127	CbGpPWpGaD
Vemurafenib—RAF1—Disease—EGFR—bone cancer	4.31e-06	0.000127	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.31e-06	0.000127	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—EGFR—bone cancer	4.28e-06	0.000126	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ENO2—bone cancer	4.25e-06	0.000125	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TP53—bone cancer	4.03e-06	0.000118	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—DHFR—bone cancer	3.94e-06	0.000116	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—JUN—bone cancer	3.84e-06	0.000113	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MMP9—bone cancer	3.74e-06	0.00011	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GSTP1—bone cancer	3.7e-06	0.000109	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GNA11—bone cancer	3.69e-06	0.000108	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TP53—bone cancer	3.67e-06	0.000108	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—EGFR—bone cancer	3.02e-06	8.89e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GSTP1—bone cancer	2.86e-06	8.41e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PTGS2—bone cancer	2.74e-06	8.07e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TP53—bone cancer	2.54e-06	7.46e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PTGS2—bone cancer	2.26e-06	6.66e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PTGS2—bone cancer	1.92e-06	5.65e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PTGS2—bone cancer	1.48e-06	4.36e-05	CbGpPWpGaD
